$KITE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kite Pharma, Inc.. Get notifications about new insider transactions in Kite Pharma, Inc. for free.
Page: < prev 1 2 3 4 5 6 ... 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 179.66 | 4,228 | 759,619 | 121,567 | 125.8 K to 121.6 K (-3.36 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Grant | A | 0.00 | 8,000 | 0 | 125,795 | 117.8 K to 125.8 K (+6.79 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | S | 179.66 | 26,347 | 4,733,605 | 109,160 | 135.5 K to 109.2 K (-19.44 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 50,000 | 0 | 135,507 | 85.5 K to 135.5 K (+58.47 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 2,656 | 136,598 | 37,344 | |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 3,595 | 193,771 | 56,407 | |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 120.09 | 6,251 | 750,683 | 18,664 | 24.9 K to 18.7 K (-25.09 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 2,656 | 136,598 | 24,915 | 22.3 K to 24.9 K (+11.93 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 3,595 | 193,771 | 22,259 | 18.7 K to 22.3 K (+19.26 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 15,000 | 20,250 | 80,394 | |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 121.03 | 5,800 | 701,974 | 117,795 | 123.6 K to 117.8 K (-4.69 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 120.52 | 9,200 | 1,108,784 | 123,595 | 132.8 K to 123.6 K (-6.93 %) |
| Aug 14 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 15,000 | 20,250 | 132,795 | 117.8 K to 132.8 K (+12.73 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 79,949 | 4,309,251 | 60,002 | |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 121.37 | 13,274 | 1,611,065 | 18,664 | 31.9 K to 18.7 K (-41.56 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 120.40 | 31,165 | 3,752,266 | 31,938 | 63.1 K to 31.9 K (-49.39 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 119.94 | 18,936 | 2,271,184 | 63,103 | 82 K to 63.1 K (-23.08 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 118.61 | 3,800 | 450,718 | 82,039 | 85.8 K to 82 K (-4.43 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 117.27 | 1,700 | 199,359 | 85,839 | 87.5 K to 85.8 K (-1.94 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 115.02 | 11,074 | 1,273,731 | 87,539 | 98.6 K to 87.5 K (-11.23 %) |
| Aug 10 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 79,949 | 4,309,251 | 98,613 | 18.7 K to 98.6 K (+428.36 %) |
| Aug 04 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | M | 44.91 | 6,000 | 269,460 | 146,000 | |
| Aug 04 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 110.05 | 5,131 | 564,667 | 49,400 | 54.5 K to 49.4 K (-9.41 %) |
| Aug 04 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 110.10 | 869 | 95,677 | 54,531 | 55.4 K to 54.5 K (-1.57 %) |
| Aug 04 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Buy | M | 44.91 | 6,000 | 269,460 | 55,400 | 49.4 K to 55.4 K (+12.15 %) |
| Aug 03 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | M | 44.91 | 3,000 | 134,730 | 152,000 | |
| Aug 03 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 109.35 | 321 | 35,101 | 49,400 | 49.7 K to 49.4 K (-0.65 %) |
| Aug 03 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 108.27 | 3,771 | 408,286 | 49,721 | 53.5 K to 49.7 K (-7.05 %) |
| Aug 03 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 107.58 | 5,431 | 584,267 | 53,492 | 58.9 K to 53.5 K (-9.22 %) |
| Aug 03 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 106.85 | 2,477 | 264,667 | 58,923 | 61.4 K to 58.9 K (-4.03 %) |
| Aug 03 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Buy | M | 44.91 | 3,000 | 134,730 | 61,400 | 58.4 K to 61.4 K (+5.14 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 16,550 | 892,045 | 139,951 | |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 10,099 | 519,392 | 40,000 | |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 111.60 | 672 | 74,995 | 18,664 | 19.3 K to 18.7 K (-3.48 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 110.55 | 2,725 | 301,249 | 19,336 | 22.1 K to 19.3 K (-12.35 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 109.74 | 7,448 | 817,344 | 22,061 | 29.5 K to 22.1 K (-25.24 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 108.75 | 15,804 | 1,718,685 | 29,509 | 45.3 K to 29.5 K (-34.88 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 16,550 | 892,045 | 45,313 | 28.8 K to 45.3 K (+57.54 %) |
| Aug 01 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 10,099 | 519,392 | 28,763 | 18.7 K to 28.8 K (+54.11 %) |
| Jul 11 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 15,000 | 20,250 | 95,394 | |
| Jul 11 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 105.50 | 5,000 | 527,500 | 117,795 | 122.8 K to 117.8 K (-4.07 %) |
| Jul 11 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 102.81 | 1,100 | 113,091 | 122,795 | 123.9 K to 122.8 K (-0.89 %) |
| Jul 11 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 102.19 | 5,553 | 567,461 | 123,895 | 129.4 K to 123.9 K (-4.29 %) |
| Jul 11 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 101.06 | 3,347 | 338,248 | 129,448 | 132.8 K to 129.4 K (-2.52 %) |
| Jul 11 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 15,000 | 20,250 | 132,795 | 117.8 K to 132.8 K (+12.73 %) |
| Jul 06 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 10,000 | 68,900 | 58,000 | |
| Jul 06 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 104.76 | 1,201 | 125,817 | 21,071 | 22.3 K to 21.1 K (-5.39 %) |
| Jul 06 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 104.26 | 8,799 | 917,384 | 22,272 | 31.1 K to 22.3 K (-28.32 %) |
| Jul 06 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 10,000 | 68,900 | 31,071 | 21.1 K to 31.1 K (+47.46 %) |
| Jun 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 101.19 | 2,050 | 207,440 | 112,795 | 114.8 K to 112.8 K (-1.79 %) |
| Jun 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 100.54 | 2,950 | 296,593 | 114,845 | 117.8 K to 114.8 K (-2.50 %) |
| Jun 26 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | M | 62.44 | 2,500 | 156,100 | 0 | |
| Jun 26 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | M | 6.89 | 10,000 | 68,900 | 10,000 | |
| Jun 26 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Sell | S | 100.60 | 12,500 | 1,257,500 | 76,250 | 88.8 K to 76.3 K (-14.08 %) |
| Jun 26 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Sell | S | 100.00 | 12,500 | 1,250,000 | 88,750 | 101.3 K to 88.8 K (-12.35 %) |
| Jun 26 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Buy | M | 62.44 | 2,500 | 156,100 | 101,250 | 98.8 K to 101.3 K (+2.53 %) |
| Jun 26 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Buy | M | 6.89 | 10,000 | 68,900 | 98,750 | 88.8 K to 98.8 K (+11.27 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Grant | A | 0.00 | 2,410 | 0 | 66,074 | 63.7 K to 66.1 K (+3.79 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Grant | A | 0.00 | 2,410 | 0 | 4,360 | 2 K to 4.4 K (+123.59 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | CLARK IAN T | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | CLARK IAN T | Director | Grant | A | 0.00 | 2,410 | 0 | 7,100 | 4.7 K to 7.1 K (+51.39 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Grant | A | 0.00 | 2,410 | 0 | 152,427 | 150 K to 152.4 K (+1.61 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Grant | A | 0.00 | 2,410 | 0 | 6,431 | 4 K to 6.4 K (+59.94 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Grant | A | 0.00 | 2,410 | 0 | 4,360 | 2 K to 4.4 K (+123.59 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Grant | A | 0.00 | 2,410 | 0 | 4,360 | 2 K to 4.4 K (+123.59 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Grant | A | 0.00 | 2,410 | 0 | 207,836 | 205.4 K to 207.8 K (+1.17 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Grant | A | 0.00 | 2,410 | 0 | 70,374 | 68 K to 70.4 K (+3.55 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Grant | A | 0.00 | 2,410 | 0 | 88,750 | 86.3 K to 88.8 K (+2.79 %) |
| Jun 16 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Sell | S | 89.48 | 20,000 | 1,789,574 | 205,426 | 225.4 K to 205.4 K (-8.87 %) |
| Jun 16 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 88.11 | 5,450 | 480,200 | 0 | 5.5 K to 0 (-100.00 %) |
| Jun 16 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 90.40 | 15,000 | 1,356,000 | 63,664 | 78.7 K to 63.7 K (-19.07 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 10,000 | 13,500 | 115,394 | |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 91.08 | 400 | 36,432 | 117,795 | 118.2 K to 117.8 K (-0.34 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 89.76 | 1,698 | 152,412 | 118,195 | 119.9 K to 118.2 K (-1.42 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 89.09 | 4,100 | 365,269 | 119,893 | 124 K to 119.9 K (-3.31 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 87.80 | 2,502 | 219,676 | 123,993 | 126.5 K to 124 K (-1.98 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 86.42 | 900 | 77,778 | 126,495 | 127.4 K to 126.5 K (-0.71 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 84.81 | 400 | 33,924 | 127,395 | 127.8 K to 127.4 K (-0.31 %) |
| Jun 12 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 10,000 | 13,500 | 127,795 | 117.8 K to 127.8 K (+8.49 %) |
| Jun 09 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 84.53 | 5,000 | 422,634 | 150,017 | 155 K to 150 K (-3.23 %) |
| Jun 09 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 84.46 | 10,000 | 844,621 | 155,017 | 165 K to 155 K (-6.06 %) |
| Jun 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 2,400 | 123,432 | 50,099 | |
| Jun 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 72.45 | 2,400 | 173,880 | 18,664 | 21.1 K to 18.7 K (-11.39 %) |
| Jun 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 2,400 | 123,432 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 68.94 | 2,632 | 181,450 | 2,632 | 0 to 2.6 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 1,029 | 71,176 | 1,029 | 0 to 1 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 2,651 | 183,370 | 2,651 | 0 to 2.7 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 3,520 | 243,478 | 3,520 | 0 to 3.5 K |
| May 10 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Buy | P | 72.59 | 3,000 | 217,770 | 3,000 | 0 to 3 K |
| May 10 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Buy | P | 72.57 | 450 | 32,657 | 7,480 | 7 K to 7.5 K (+6.40 %) |
| May 10 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Buy | P | 69.50 | 1,400 | 97,300 | 225,426 | 224 K to 225.4 K (+0.62 %) |
| May 09 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Buy | P | 70.15 | 3,815 | 267,622 | 2,408,084 | 2.4 M to 2.4 M (+0.16 %) |
| May 09 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Buy | P | 68.84 | 46,185 | 3,179,375 | 2,404,269 | 2.4 M to 2.4 M (+1.96 %) |
| May 09 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | P | 68.57 | 17,000 | 1,165,690 | 85,507 | 68.5 K to 85.5 K (+24.81 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 2,400 | 129,360 | 156,501 | |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 82.12 | 2,400 | 197,088 | 18,664 | 21.1 K to 18.7 K (-11.39 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 2,400 | 129,360 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 20,000 | 137,800 | 123,000 | |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 83.36 | 300 | 25,008 | 50,165 | 50.5 K to 50.2 K (-0.59 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.60 | 5,905 | 487,753 | 50,465 | 56.4 K to 50.5 K (-10.48 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 81.84 | 13,795 | 1,128,983 | 56,370 | 70.2 K to 56.4 K (-19.66 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 20,000 | 137,800 | 70,165 | 50.2 K to 70.2 K (+39.87 %) |
| May 01 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.59 | 2,617 | 216,138 | 4,962 | 7.6 K to 5 K (-34.53 %) |
| May 01 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.77 | 16,551 | 1,369,926 | 7,579 | 24.1 K to 7.6 K (-68.59 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 15,000 | 20,250 | 125,394 | |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 82.87 | 3,742 | 310,100 | 117,795 | 121.5 K to 117.8 K (-3.08 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 82.14 | 5,545 | 455,466 | 121,537 | 127.1 K to 121.5 K (-4.36 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 80.89 | 5,713 | 462,125 | 127,082 | 132.8 K to 127.1 K (-4.30 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 15,000 | 20,250 | 132,795 | 117.8 K to 132.8 K (+12.73 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 83.06 | 200 | 16,612 | 24,130 | 24.3 K to 24.1 K (-0.82 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.72 | 51,112 | 4,227,985 | 24,330 | 75.4 K to 24.3 K (-67.75 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 83.29 | 15,316 | 1,275,670 | 75,442 | 90.8 K to 75.4 K (-16.88 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.56 | 31,467 | 2,597,916 | 90,758 | 122.2 K to 90.8 K (-25.75 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.34 | 25,818 | 2,125,854 | 122,225 | 148 K to 122.2 K (-17.44 %) |
| Apr 17 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 83.06 | 100 | 8,306 | 148,043 | 148.1 K to 148 K (-0.07 %) |
| Apr 17 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.48 | 43,001 | 3,546,722 | 148,143 | 191.1 K to 148.1 K (-22.50 %) |
| Apr 17 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.39 | 72,275 | 5,954,737 | 191,144 | 263.4 K to 191.1 K (-27.44 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 20,000 | 137,800 | 143,000 | |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 83.66 | 700 | 58,562 | 50,165 | 50.9 K to 50.2 K (-1.38 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.60 | 8,697 | 718,372 | 50,865 | 59.6 K to 50.9 K (-14.60 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.00 | 3,549 | 291,018 | 59,562 | 63.1 K to 59.6 K (-5.62 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 80.44 | 2,424 | 194,987 | 63,111 | 65.5 K to 63.1 K (-3.70 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.63 | 3,939 | 313,663 | 65,535 | 69.5 K to 65.5 K (-5.67 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 78.53 | 691 | 54,264 | 69,474 | 70.2 K to 69.5 K (-0.98 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 20,000 | 137,800 | 70,165 | 50.2 K to 70.2 K (+39.87 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 10,000 | 13,500 | 145,394 | |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 78.75 | 400 | 31,500 | 117,795 | 118.2 K to 117.8 K (-0.34 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 78.10 | 4,925 | 384,643 | 118,195 | 123.1 K to 118.2 K (-4.00 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 77.23 | 4,375 | 337,881 | 123,120 | 127.5 K to 123.1 K (-3.43 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 75.74 | 300 | 22,722 | 127,495 | 127.8 K to 127.5 K (-0.23 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 10,000 | 13,500 | 127,795 | 117.8 K to 127.8 K (+8.49 %) |
| Mar 16 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | A | 83.89 | 17,130 | 1,437,036 | 17,130 | |
| Mar 16 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Grant | A | 0.00 | 4,690 | 0 | 86,340 | 81.7 K to 86.3 K (+5.74 %) |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 21,118 | 28,509 | 155,394 | |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 81.20 | 8,991 | 730,069 | 117,795 | 126.8 K to 117.8 K (-7.09 %) |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 80.47 | 12,127 | 975,860 | 126,786 | 138.9 K to 126.8 K (-8.73 %) |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 21,118 | 28,509 | 138,913 | 117.8 K to 138.9 K (+17.93 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 18,000 | 124,020 | 68,000 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 79.83 | 160 | 12,773 | 21,071 | 21.2 K to 21.1 K (-0.75 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 78.97 | 311 | 24,560 | 21,231 | 21.5 K to 21.2 K (-1.44 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 76.98 | 150 | 11,547 | 21,542 | 21.7 K to 21.5 K (-0.69 %) |